5-Aminosalicylic acid exhibits anti-inflammatory, antioxidative, and anticancer activities; it is clinically used to treat inflammatory bowel disease (IBD), Crohn’s disease, and colitis, as it acts primarily in the colon. In vitro, 5-aminosalicylic acid decreases levels of ROS, increases levels of catalase and PPARγ, and stimulates PTEN signaling. In colorectal cancer cells, this compound decreases proliferation by inhibiting phospholipase D (PLD) activity and mTOR signaling.
| Cas No. | 89-57-6 |
|---|---|
| Purity | ≥98% |
| Formula | C7H7NO3 |
| Formula Wt. | 153.14 |
| Chemical Name | 5-amino-2-hydroxybenzoic acid |
| IUPAC Name | 5-amino-2-hydroxybenzoic acid |
| Synonym | 5-ASA; Mesalamine; Asacol; Salofalk; 5-amino-2- hydroxybenzoic acid |
| Melting Point | 275-280°C (dec) |
| Appearance | A white or almost white crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | A5035 MSDS PDF |
|---|---|
| Info Sheet | A5035 Info Sheet PDF |
Poh J, Knowles S. Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs. Can J Hosp Pharm. 2014 Jan;67(1):35-8. PMID: 24634525.
Managlia E, Katzman RB, Brown JB, et al. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis. 2013 Sep;19(10):2051-60. PMID: 23867870.
Baan B, Dihal AA, Hoff E, et al. 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut. 2012 Dec;61(12):1708-15. PMID: 22187071.
